↓ Skip to main content

Disease burden of chronic hepatitis C in Brazil

Overview of attention for article published in The Brazilian Journal of Infectious Diseases, June 2015
Altmetric Badge

Mentioned by

1 news outlet


16 Dimensions

Readers on

72 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Disease burden of chronic hepatitis C in Brazil
Published in
The Brazilian Journal of Infectious Diseases, June 2015
DOI 10.1016/j.bjid.2015.04.004
Pubmed ID

Ferreira, Paulo Roberto Abrão, Brandão-Mello, Carlos Eduardo, Estes, Chris, Júnior, Fernando Lopes Gonçales, Coelho, Henrique Sérgio Moraes, Razavi, Homie, Cheinquer, Hugo, Wolff, Fernando Herz, Ferraz, Maria Lúcia Gomes, Pessoa, Mário Guimarães, Correa, Maria Cássia Mendes


Hepatitis C virus infection is a major cause of cirrhosis; hepatocellular carcinoma; and liver transplantation. The aim of this study was to estimate hepatitis C virus disease progression and the burden of disease from a nationwide perspective. Using a model developed to forecast hepatitis C virus disease progression and the number of cases at each stage of liver disease; hepatitis C virus-infected population and associated disease progression in Brazil were quantified. The impact of two different strategies was compared: higher sustained virological response and treatment eligibility rates (1) or higher diagnosis and treatment rates associated with increased sustained virological response rates (2). The number of infected individuals is estimated to decline by 35% by 2030 (1,255,000 individuals); while the number of cases of compensated (n=325,900) and decompensated (n=45,000) cirrhosis; hepatocellular carcinoma (n=19,100); and liver-related deaths (n=16,700) is supposed to peak between 2028 and 2032. In strategy 2; treated cases increased over tenfold in 2020 (118,800 treated) as compared to 2013 (11,740 treated); with sustained virological response increased to 90% and treatment eligibility to 95%. Under this strategy; the number of infected individuals decreased by 90% between 2013 and 2030. Compared to the base case; liver-related deaths decreased by 70% by 2030; while hepatitis C virus-related liver cancer and decompensated cirrhosis decreased by 75 and 80%; respectively. While the incidence and prevalence of hepatitis C virus in Brazil are decreasing; cases of advanced liver disease continue to rise. Besides higher sustained virological response rates; new strategies focused on increasing the proportion of diagnosed patients and eligibility to treatment should be adopted in order to reduce the burden of hepatitis C virus infection in Brazil.

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 3%
Unknown 70 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 18%
Student > Bachelor 11 15%
Student > Postgraduate 9 13%
Student > Ph. D. Student 8 11%
Student > Doctoral Student 5 7%
Other 13 18%
Unknown 13 18%
Readers by discipline Count As %
Medicine and Dentistry 23 32%
Agricultural and Biological Sciences 9 13%
Biochemistry, Genetics and Molecular Biology 4 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Economics, Econometrics and Finance 3 4%
Other 10 14%
Unknown 20 28%